G-CSF cost-neutral for early-stage breast cancer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.646, 2012-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Economic Evaluation and Decision Making: Reimbursing Trastuzumab in Early-Stage Breast Cancer

By Simoens Steven

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 181-185

Adis International

Access to resources Recommend Favorite

Quality-of-Life Considerations in the Treatment of Early-Stage Breast Cancer in the Elderly

By Reimer Toralf Gerber Bernd

Drugs & Aging, Vol. 27, Iss. 10, 2010-10 ,pp. : 791-800

Adis International

Access to resources Recommend Favorite

Trastuzumab in Early-Stage Breast Cancer: The Question of Treatment Timing

By Simoens Steven

PharmacoEconomics, Vol. 26, Iss. 10, 2008-01 ,pp. : 807-809

Adis International

Access to resources Recommend Favorite

Anastrozole: A Review of its Use in Postmenopausal Women with Early-Stage Breast Cancer

By Sanford Mark Plosker Greg L.

Drugs, Vol. 68, Iss. 9, 2008-01 ,pp. : 1319-1340

Adis International

Access to resources Recommend Favorite

Letrozole: In Postmenopausal Hormone-Responsive Early-Stage Breast Cancer

By Scott Lesley J. Keam Susan J.

Drugs, Vol. 66, Iss. 3, 2006-01 ,pp. : 353-362

Adis International

Access to resources Recommend Favorite